成釉细胞瘤靶向治疗靶点及相关药物研究进展

Research advances in targeted therapy and related drugs for ameloblastoma

成釉细胞瘤是常见的口腔颌面部良性肿瘤,手术切除为治疗首选,但切除术易引起颌面畸形和功能丧失,且术后复发率较高,目前对于多次复发和转移成釉细胞瘤仍没有有效的治疗措施。针对成釉细胞瘤治疗研究热点集中在以靶向治疗联合手术的综合治疗方式。在过去十余年间,随着分子生物学的发展,尤其分子靶点如BRAF、SMO被发现,相关药物如维莫非尼已开始初步应用于临床,并取得了一定的效果。靶向治疗作用机制的研究可进一步提高成釉细胞瘤治愈率并减少复发和转移,本文就成釉细胞瘤靶向治疗靶点及相关药物研究进展进行综述。

Ameloblastomas are common benign tumors of the oral and maxillofacial region and surgical excision is preferred for the management of this tumor.However,resection can easily cause maxillofacial deformities and loss of function,and the postoperative recurrence rate is high.Currently,there is still no effective treatment for multiple recurrences and metastases of ameloblastoma.Research hotspots for ameloblastoma treatment have focused on comprehensive treatment modalities in the form of targeted therapies combined with surgery.Over the past decade or so,with the development of molecular biology,especially molecular targets such as BRAF and SMO were discovered,related drugs such as Vemurafenib have begun to be used initially in the clinic and have achieved certain results.Research on the mechanism of action of targeted therapy can further improve the ameloblastoma cure rate and reduce recurrence and metastasis,and this article provides a review of the progress of targeted therapy targets and related drugs for ameloblastoma.